Compare Stocks: ACHL, SLGL, SIGA, and ANTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	744,051 shs	N/A
ANTX Anthem	$5.91 -0.3%	$4.84	$1.00 ▼ $6.91	$213.58M	-0.99	195,500 shs	91,245 shs
SIGA Siga Technologies	$2.93 -3.9%	$3.75	$2.86 ▼ $9.62	$219.14M	0.97	785,568 shs	1.02 million shs
SLGL Sol-Gel Technologies	$84.74 -3.7%	$77.69	$14.78 ▼ $97.97	$247.27M	1.12	52,374 shs	84,318 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ANTX Anthem	0.00%	+10.84%	+31.78%	+25.64%	+454.21%
SIGA Siga Technologies	0.00%	-6.73%	-15.04%	-32.97%	-65.96%
SLGL Sol-Gel Technologies	0.00%	+6.99%	+19.00%	+25.75%	+450.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	744,051 shs	N/A
ANTX Anthem	$5.91 -0.3%	$4.84	$1.00 ▼ $6.91	$213.58M	-0.99	195,500 shs	91,245 shs
SIGA Siga Technologies	$2.93 -3.9%	$3.75	$2.86 ▼ $9.62	$219.14M	0.97	785,568 shs	1.02 million shs
SLGL Sol-Gel Technologies	$84.74 -3.7%	$77.69	$14.78 ▼ $97.97	$247.27M	1.12	52,374 shs	84,318 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ANTX Anthem	0.00%	+10.84%	+31.78%	+25.64%	+454.21%
SIGA Siga Technologies	0.00%	-6.73%	-15.04%	-32.97%	-65.96%
SLGL Sol-Gel Technologies	0.00%	+6.99%	+19.00%	+25.75%	+450.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ANTX Anthem	2.33	Hold	$9.00	52.28% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	133.07% Upside

Current Analyst Ratings Breakdown

Latest ACHL, SLGL, SIGA, and ANTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	ANTX Anthem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/6/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
6/24/2026	SLGL Sol-Gel Technologies	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$285.00
6/15/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
6/4/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
5/29/2026	SLGL Sol-Gel Technologies	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
5/28/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
5/22/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D+)
5/15/2026	SLGL Sol-Gel Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
SIGA Siga Technologies	$94.57M	2.23	$0.32 per share	9.16	$2.78 per share	1.05
SLGL Sol-Gel Technologies	$19.39M	12.28	N/A	N/A	$8.19 per share	10.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	N/A
ANTX Anthem	-$35.17M	-$1.10	N/A	N/A	N/A	N/A	-52.35%	-47.25%	N/A
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.51%	-1.25%	N/A
SLGL Sol-Gel Technologies	-$6.13M	-$0.34	N/A	N/A	N/A	-5.66%	-3.17%	-2.58%	8/21/2026 (Estimated)

Latest ACHL, SLGL, SIGA, and ANTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	N/A	N/A	N/A	$0.08 million	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million
5/28/2026	Q1 2026	SLGL Sol-Gel Technologies	-$2.86	-$1.31	+$1.55	$1.31	$0.90 million	$0.11 million
5/11/2026	Q1 2026	ANTX Anthem	-$0.23	-$0.29	-$0.06	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
ANTX Anthem	N/A	15.73	15.73
SIGA Siga Technologies	N/A	3.25	2.38
SLGL Sol-Gel Technologies	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
ANTX Anthem	90.47%
SIGA Siga Technologies	55.40%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
ANTX Anthem	22.61%
SIGA Siga Technologies	2.73%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ANTX Anthem	N/A	36.02 million	27.87 million	Not Optionable
SIGA Siga Technologies	40	71.85 million	69.89 million	Optionable
SLGL Sol-Gel Technologies	50	2.81 million	941,000	No Data

ACHL, SLGL, SIGA, and ANTX Headlines

Recent News About These Companies

Affinity Asset Advisors LLC Purchases Shares of 35,000 Sol-Gel Technologies Ltd. $SLGL

July 25, 2026 | marketbeat.com

Sol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | Benzinga

July 23, 2026 | benzinga.com

HC Wainwright Issues Positive Estimate for SLGL Earnings

July 22, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Sol-Gel Technologies (NASDAQ:SLGL)

July 20, 2026 | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages

July 18, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 Shares

July 11, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in Stock

July 3, 2026 | insidertrades.com

Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities

June 26, 2026 | theglobeandmail.com

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

May 30, 2026 | theglobeandmail.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

May 28, 2026 | zacks.com

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 28, 2026 | globenewswire.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of Stock

May 15, 2026 | insidertrades.com

Sol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary Shares

March 23, 2026 | quiverquant.comQ

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

March 23, 2026 | globenewswire.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates

March 19, 2026 | zacks.com

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

March 19, 2026 | globenewswire.com

This Under-the-Radar Stock Has Surged 1,300% Over the Past Year

March 13, 2026 | finance.yahoo.com

Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year

February 11, 2026 | finance.yahoo.com

Sol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20

February 4, 2026 | msn.com

Opaleye Management Inc. Buys 1,151 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

January 24, 2026 | insidertrades.com

Sol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 Catalyst

January 18, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, SLGL, SIGA, and ANTX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Anthem NASDAQ:ANTX

$5.91 -0.02 (-0.34%)

As of 04:00 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Siga Technologies NASDAQ:SIGA

$2.93 -0.12 (-3.93%)

As of 04:00 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Sol-Gel Technologies NASDAQ:SLGL

$84.74 -3.26 (-3.70%)

As of 04:00 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHL, SLGL, SIGA, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHL, SLGL, SIGA, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHL, SLGL, SIGA, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, SLGL, SIGA, and ANTX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Anthem NASDAQ:ANTX

Siga Technologies NASDAQ:SIGA

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHL, SLGL, SIGA, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHL, SLGL, SIGA, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHL, SLGL, SIGA, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, SLGL, SIGA, and ANTX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Anthem NASDAQ:ANTX

Siga Technologies NASDAQ:SIGA

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools